39 results on '"Rumi, Filippo"'
Search Results
2. The economic and social burden of atopic dermatitis in Italy: a Cost-of-Illness analysis.
- Author
-
Antonini, Debora, Rumi, Filippo, Basile, Michele, Di Brino, Eugenio, Fortunato, Agostino, Siviero, Ludovica, and Cicchetti, Americo
- Subjects
ATOPIC dermatitis treatment ,ATOPIC dermatitis ,NATIONAL health services ,RESEARCH funding ,COST analysis ,DISEASE management ,DESCRIPTIVE statistics ,SOCIAL attitudes ,ECONOMIC aspects of diseases ,MEDICAL care costs - Abstract
Background: Atopic dermatitis, also known as atopic eczema, is a chronic, relapsing inflammatory, and eczematous skin disease. The clinical presentation of atopic dermatitis is characterized by erythematous, pruritic, dry, scaly, and often lichenified skin. The epidemiology of atopic dermatitis can vary greatly among countries, and across different age groups. Currently, atopic dermatitis doesn’t have a resolving treatment. Consequently, the purpose of management is to improve symptoms and achieve long-term disease control. Atopic dermatitis generates a considerable consumption of resources, developing significant economic consequences for patients, healthcare systems, and society. This study aimed to estimate the economic and social burden for atopic dermatitis patients in the Italian context. Methods: A Cost of Illness analysis was developed. Two perspectives of analysis were established for the study: the National Health System perspective and the societal perspective. Therefore, direct healthcare and non-healthcare costs, and indirect costs were included in the analysis. Data were identified and measured through the administration of a survey to patients affected by atopic dermatitis. Results: The annual total cost of a patient for the management of atopic dermatitis is equal to € 7,041.12. Within the overall cost per patient, direct health care costs (€ 3,290.69) accounting for 46.74% of the total expenditure, indirect costs (€ 1,924.92) accounting for 25.93% of the expenditure, and finally out-of-pocket expenses accounting for 27.34% of the expenditure being valued at € 1,825.52. Conclusion: The Cost of Illness analysis carried out underlines how atopic dermatitis places a significant financial burden on the healthcare system, but even more so on patients affected by this condition. Indirect costs and out-of-pocket expenditures, such as those related to the purchase of drugs, non-pharmacological treatment, and lost working days, represent the most important items of the atopic dermatitis economic and social burden. [ABSTRACT FROM AUTHOR]
- Published
- 2024
3. Eosinophilic esophagitis in adults and adolescents: epidemiology, diagnostic challenges, and management strategies for a type 2 inflammatory disease.
- Author
-
Savarino, Edoardo Vincenzo, Barbara, Giovanni, Bilò, Maria Beatrice, De Bortoli, Nicola, Di Sabatino, Antonio, Oliva, Salvatore, Penagini, Roberto, Racca, Francesca, Tortora, Annalisa, Rumi, Filippo, and Cicchetti, Americo
- Subjects
EOSINOPHILIC esophagitis ,LITERATURE reviews ,EVIDENCE gaps ,ELIMINATION diets ,ADULTS ,EPIDEMIOLOGY - Abstract
Background: Eosinophilic esophagitis (EoE) is recognized as a chronic type 2 inflammatory disease characterized by the eosinophilic infiltration of the esophageal tissue, posing a significant disease burden and highlighting the necessity for novel management strategies to address unmet clinical needs. Objectives: To critically evaluate the existing literature on the epidemiology and management of EoE, identify evidence gaps, and assess the efficacy of current and emerging treatment modalities. Design: An extensive literature review was conducted, focusing on the epidemiological trends, diagnostic challenges, and therapeutic interventions for EoE. This was complemented by a survey among physicians and consultations with a scientific expert panel, including a patient's association (ESEO Italia), to enrich the study findings. Data sources and methods: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, scrutinizing epidemiological studies and management research to compile comprehensive insights into the disease's landscape. The physician survey and expert panel discussions aimed to bridge identified evidence gaps. Results: The review included 59 epidemiological and 51 management studies, uncovering variable incidence and prevalence rates of EoE globally, with an estimated diagnosed prevalence of 41 per 100,000 in Italy. Diagnostic challenges were identified, including nonspecific symptoms and the lack of definitive biomarkers, which complicate the use of endoscopy. Treatment options such as elimination diets, proton-pump inhibitors, and swallowed corticosteroids were found to have varying success rates, while Dupilumab, an emerging therapy targeting interleukin (IL)-4 and IL-13, shows promise. Conclusion: Despite advancements in understanding and managing EoE, significant unmet clinical needs remain, particularly in biomarker identification, therapy personalization, and cost-effectiveness evaluation. A comprehensive, multidimensional approach to patient management is required, emphasizing the importance of early symptom recognition, accurate diagnosis, and tailored treatment strategies. Dupilumab offers potential as a novel treatment, underscoring the need for future research to explore the economic and social dimensions of EoE care pathways. Plain language summary: Understanding and improving care for eosinophilic esophagitis: bridging gaps in diagnosis and treatment Eosinophilic esophagitis (EoE) is a chronic inflammatory condition affecting the esophagus. We reviewed studies on how common EoE is and how it's managed. In Italy, about 41 out of 100,000 people may have it. Diagnosis can be tricky due to vague symptoms, and current treatments vary in effectiveness. We found a need for better ways to diagnose and treat EoE, including exploring new therapies. A promising development is a biologic called Dupilumab. Future research should also consider the costs and social aspects of caring for people with EoE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. A budget impact model and a cost-utility analysis of reducer device (Neovasc) in patients with refractory angina.
- Author
-
Fortunato, Agostino, Valentini, Ilaria, Rumi, Filippo, Antonini, Debora, Siviero, Ludovica, Di Brino, Eugenio, Basile, Michele, and Cicchetti, Americo
- Published
- 2024
- Full Text
- View/download PDF
5. Analisi economica-organizzativa del percorso riabilitativo nei pazienti con lesione midollare: Il Montecatone Rehabilitation Institute.
- Author
-
Fortunato, Agostino, Giorgio, Luca, Laurita, Roberta, Rumi, Filippo, Cicchetti, Americo, Cava, Nicoletta, Balloni, Mimosa, Ferrara, Giovanna, and Albertazzi, Stefania
- Subjects
SPINAL cord injuries ,REHABILITATION centers ,FOCUS groups ,MEDICAL care costs ,NEUROGENIC bowel ,MEDICAL protocols ,RISK assessment ,LABOR supply ,HEALTH care teams ,DECISION making ,QUALITY of life ,PATIENT care ,CORPORATE culture ,DISCHARGE planning ,ECONOMICS ,DISEASE risk factors - Abstract
Copyright of Giornale Italiano di Health Technology Assessment Delivery is the property of Springer Healthcare Italia Srl and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
6. Analisi retrospettiva dei costi e di outcome sanitari in pazienti affetti da asma grave in un contesto real-world: il caso di studio benralizumab.
- Author
-
Rumi, Filippo, Fortunato, Agostino, Antonini, Debora, Graziani, Elda, Masieri, Simonetta, Modica, Stella, Tourtchenko, Victoria, Coppola, Angelo, Ferrara, Luca, Zobel, Sara Beomonte, Bonini, Matteo, Caruso, Cristiano, Cavaliere, Carlo, Cattani, Luciano, Barbaglia, Simona, and Monaco, Alessandro
- Subjects
DRUG therapy for asthma ,THERAPEUTIC use of monoclonal antibodies ,EVALUATION of medical care ,LABOR productivity ,JOB absenteeism ,HEALTH status indicators ,RETROSPECTIVE studies ,COST analysis ,HOSPITAL care ,QUALITY of life ,QUESTIONNAIRES - Abstract
Copyright of Giornale Italiano di Health Technology Assessment Delivery is the property of Springer Healthcare Italia Srl and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
7. The added value of applying a disinvestment approach to the process of health technology assessment in Italy.
- Author
-
Cadeddu, Chiara, Regazzi, Luca, Di Brino, Eugenio, Basile, Michele, Cascini, Fidelia, Paladini, Andrea, Rumi, Filippo, Cicchetti, Americo, and Ricciardi, Walter
- Abstract
Objectives: The objective of the present policy analysis was to understand how a disinvestment approach to the process of health technology assessment (HTA), applied to the field of medical devices, might help Italian policymakers to properly spend the resources in healthcare. Methods: Previous international and national experiences in disinvestment for medical devices were reviewed. Precious insights for the rational expenditure of the resources were derived by assessing the evidence available. Results: The disinvestment of ineffective or inappropriate technologies or interventions with an inadequate value-for-money ratio has become a growing priority for National Health Systems. Different international disinvestment experiences of medical devices were identified and described through a rapid review. Although most of them have a strong theoretical framework, their practical application remains difficult. In Italy, there are no examples of large and complex HTA-based disinvestment practices, but their importance is becoming increasingly acknowledged, especially given the need to prioritize the funds provided by Recovery and Resilience Plan. Conclusions: Anchoring decisions on health technologies without reassessing the current technological landscape through a robust HTA model might expose to the risk of not ensuring the best employment of the resources available. Thus, it is necessary to develop a strong HTA ecosystem in Italy through adequate consultation with stakeholders to enable a data-driven and evidence-based prioritization of resources toward choices characterized by high value for both patients and society as a whole. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
- Author
-
Di Brino, Eugenio, Yan, Songkai, Tomic, Radovan, Panebianco, Marco, Dlotko, Ewa, Stern, Lee, Basile, Michele, Rumi, Filippo, Cicchetti, Americo, and Marino, Renato
- Subjects
HEMOPHILIA ,PUBLIC health ,MEDICAL technology ,HEALTH outcome assessment ,MEDICAL economics - Abstract
rVIII-SingleChain, a recombinant factor VIII (rFVIII), has demonstrated safety and efficacy in patients with hemophilia A in clinical trials and real-world evidence. This analysis aimed to estimate the potential budget impact of increasing the usage of rVIII-SingleChain for the prophylactic treatment of hemophilia A over 3 years in Italy. Patients with moderate and severe hemophilia A receiving prophylaxis were included in the analysis. Epidemiological data were obtained from published literature. Mean product consumption and mean annual bleeding rate for rVIII-SingleChain, rFVIIIFc, octocog alfa and BAY 81-8973 were based on pooled real-world data from Italy, Germany and US. A budget impact model has been developed in order to compare two scenarios: a base-case scenario where current rVIII-SingleChain shares are kept constant over 3 years and an alternative scenario where rVIII-SingleChain shares increase by taking from other rFVIII products. Analysis 1 was based on the current Italian list prices and Analysis 2 considered current regional acquisition prices for both scenarios. Annually, adult patients treated with rVIII-SingleChain prophylaxis are expected to consume 324,589 units per patient, resulting in annual costs of €240,196 per patient. In Analysis 1, comparing the base case (constant market share of 9% rVIII-SingleChain over time) with the alternative scenario (higher rVIII-SingleChain market share and increasing from 15% in the first year to 25% in the third year), the total expenditure for prophylaxis using rFVIII products is expected to decrease by €1.4 million in Year 1, by €3.1 million in Year 2 and by €5.4 million in Year 3. In Analysis 2 based on regional prices, the results remained consistent. This analysis suggests that increasing utilization of rVIII-SingleChain in hemophilia A patients may lead to cost savings as a result of reduced consumption with uncompromised efficacy in bleed protection. Why was the study done? Hemophilia A is a rare inherited bleeding disorder. People with severe hemophilia are more likely to bleed compared to people without hemophilia and bleeds can occur spontaneously or in response to trauma. Patients are treated with medication to reduce the chance of bleeding. However, the cost of treating patients with hemophilia can be high and place demands on the healthcare system. What did we do and find? This study looked at the cost of treating people with hemophilia in Italy and used a type of economic analysis (called budget impact modelling) to estimate the effect of increasing the use of a particular medication (rVIII-SingleChain), compared to other medications that are available. Different variations of the model were tested to compare a range of scenarios. The results of this analysis suggested that increasing the use of rVIII-SingleChain may lead to cost-savings for the Italian healthcare system, compared to using the other currently available treatments. This analysis suggests that the use of rVIII-SingleChain enables people with hemophilia A to remain protected from bleeds, whilst using less product compared to other available medications. What is the influence of this study on the wider field? This type of analysis can be useful to healthcare systems, to guide the decision-making process regarding which medications to use or when making decisions related to healthcare policy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Value for Patient - risultati di un laboratorio applicativo di Value Based Healthcare per la gestione delle malattie da accumulo lisosomiale in 3 Regioni italiane.
- Author
-
Di Brino, Eugenio, Basile, Michele, Rumi, Filippo, Fortunato, Agostino, Antonini, Debora, Annicchiarico, Giuseppina, Limongelli, Giuseppe, Piccione, Maria, Filippelli, Amelia, and Cicchetti, Americo
- Subjects
EVALUATION of medical care ,HEALTH facilities ,STAKEHOLDER analysis ,LYSOSOMAL storage diseases ,VALUE-based healthcare ,THEMATIC analysis ,RARE diseases ,ADULT education workshops - Abstract
Copyright of Giornale Italiano di Health Technology Assessment Delivery is the property of Springer Healthcare Italia Srl and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
10. The Economic and Fiscal Impact of Influenza Vaccination for Health Care Workers in Italy.
- Author
-
Calabrò, Giovanna Elisa, Rumi, Filippo, Fallani, Elettra, Ricciardi, Roberto, and Cicchetti, Americo
- Subjects
MEDICAL personnel ,INFLUENZA vaccines ,ECONOMIC impact ,VACCINATION coverage ,ECONOMIC systems - Abstract
Influenza has a significant impact on the health care system and also on production and economic systems. Vaccinated health care workers (HCWs) are more likely to have improved productivity compared to unvaccinated workers. The study aim was to estimate the economic and fiscal impact of an influenza vaccination program for HCWs in Italy. We performed a cost analysis aimed to estimate the indirect costs (productivity losses due to working days lost) and the increase in tax revenues derived from the increase in vaccination coverage among HCWs. Assuming an incremental increase in vaccination coverage of 10% per year over a period of 5 years, total savings could be obtained in terms of a reduction in productivity losses equal to −€4,475,497.16 and an increase in tax revenues of €327,158.84. This revenue could be used to finance other health interventions. Our results are fundamental in view of the sustainability of health systems and of a value-based allocation of health resources. Therefore, a complete social perspective, including the fiscal impact of flu vaccination, should be adopted to assess the economic value of influenza vaccines. Currently, health policies based on the whole value of flu vaccination are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Project NeReA (Network Regionale Asma grave) 2021 - Addressing the needs of severe asthma patient in the Lazio Region.
- Author
-
Bonini, Matteo, Cattani, Luciano, Chiriatti, Alberto, Ferrante, Fulvio, Graziani, Elda, Macciocchi, Bruno, Petrangolini, Teresa, Ricciardulli, Daniela, Maria Ricciuto, Giulio, Rogliani, Paola, Rumi, Filippo, Sarni, Antonella, Sebastiani, Alfredo, Silenzi, Andrea, Zappa, Maria Cristina, and Monaco, Alessandro
- Published
- 2022
12. Le modalità distributive dei presidi per stomia e incontinenza nel setting sanitario italiano: un questionario di valutazione e il burden sociale della distribuzione diretta.
- Author
-
Rumi, Filippo, Orsini, Francesca, Falabella, Vincenzo, Spena, Pier Raffaele, and Cicchetti, Americo
- Abstract
Background: The distribution of ostomy and incontinence devices takes place through different modalities according to the regional provisions in force. A first possibility is represented by direct distribution by the local health authorities. A second possibility consists of indirect distribution through affiliated retailers, typically pharmacies and authorized retailers of medical devices. A third form of distribution concerns home distribution. Methods: A survey has been administered to patients' associations in order to investigate the degree of patients' satisfaction with the distribution methods of medical devices necessary for the conditions associated with ostomy and incontinence and to provide an estimate of the indirect costs associated with distribution methods in the Italian healthcare context through the development of a budget impact model. Results: The distribution methods associated with a greater degree of satisfaction seem to be indirect and home distribution. Regarding the results of the budget impact mode, in our simulation, a diffusion of home distribution compared to direct and indirect distribution could lead to savings equal to 2,479,519 € over the three-year time horizon considered. Conclusion: The analysis conducted demonstrates how an increase in home distribution in the context of devices associated with people with ostomy or who practice self-catheterization can be associated with resource savings for the entire society (indirect costs avoided). The survey also demonstrates how this distribution method is associated with a good degree of satisfaction on the part of the users who use it. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Budget impact analysis sull'introduzione del dispositivo di telemonitoraggio Turbo+ nella gestione dei pazienti asmatici in Italia.
- Author
-
Rumi, Filippo, Basile, Michele, Cicchetti, Americo, Contiguglia, Rosario, Pentassuglia, Antonella, Oliva, Alessandro, Senna, Gianenrico, Bonavia, Marco, Scarpelli, Francesco, and Benvenuto, Marco
- Abstract
Introduction: Adherence to long-term asthma control drugs is one of the key factors in improving disease management among patients with asthma. Poor adherence to long-term therapies significantly compromises the effectiveness of treatment and represents a problem in controlling the disease in terms of quality of life and economic impact. A budget impact analysis has been developed taking into account that Turbo+ technology (electronic monitoring device) can increase adherence to therapy in patients suffering from asthma. Methods: Coherently with the budget impact model methodology, we developed two different scenarios. One represents the clinical practice assuming a constant market share of 0,99% for Turbo+ and the other one assumes an incremental market share of Turbo+ over the time horizon considered. An increase in adherence to therapy will likely correspond to a reduction of exacerbations and a lower rate of hospitalizations, thus generating savings in terms of use of health resources. Results: The differential analysis shows an incremental saving in terms of resources absorbed by the National Health Service (NHS) over the time horizon considered. In the first year the savings are equal to € 795,658.64 and in the fifth year they are equal to € 3,520,636.34 for a total of resources saved in 5 years of € 10,882,028.50. Conclusions: The model shows how the diffusion of the Turbo+ programme can lead to savings in terms of health resources consumed by the NHS. Further analyses with new real-world data on adherence in asthmatic patients could be useful in confirming the results of the present analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Valutazione economica dell'aderenza terapeutica e il suo impatto sul management del paziente affetto da osteoartrosi e depressione.
- Author
-
Basile, Michele, Rumi, Filippo, and Cicchetti, Americo
- Abstract
Copyright of Giornale Italiano di Health Technology Assessment Delivery is the property of Springer Healthcare Italia Srl and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
15. Analisi di costo-efficacia e budget impact per il vaccino antinfluenzale quadrivalente ad alto dosaggio nella popolazione anziana italiana.
- Author
-
Rumi, Filippo, Basile, Michele, and Cicchetti, Americo
- Abstract
Introduction: Influenza is a widespread acute respiratory disease and represents a serious Public Health problem, both from the NHS and society perspectives. The High Dose quadrivalent influenza vaccine (QIV HD) is a flu vaccine containing 4 times the antigens of a Standard Dose vaccine, resulting in demonstrated superior protection in the population aged 65 years and over. Methods: The analysis has been conducted from the perspective of the NHS. The CEA focuses on the comparison between QIV HD and the QIV SD vaccine. The BIM aims to estimate the potential economic impact for the National Health Service (NHS) resulting from the use of QIV HD in clinical practice in subjects aged 65 or over, when considering its introduction in combination with currently used vaccines, QIV SD and adjuvanted TIV. Results: In a scenario which considers hospitalizations possibly related to influenza, so including cardio-respiratory events, a dominant cost-effectiveness profile emerges in the comparison with QIV SD. In terms of budget impact, overall savings obtained by comparing the two scenarios regarding hospitalizations are equal to 92,766,429 € over the three years' time horizon considered in the analysis. Conclusions: Nowadays, also considering the state of emergency due to the spread of the SARS-CoV-2 virus, it is crucial to implement innovative health technologies that improve the efficiency and sustainability of the health system. Also, it is essential to protect the elderly population, helping to avoid overload and healthcare systems disruption due to the many COVID-19 hospitalizations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Analisi di Budget Impact di ponatinib per il management di pazienti affetti da leucemia mieloide cronica.
- Author
-
Basile, Michele, Rumi, Filippo, and Cicchetti, Americo
- Abstract
Background: The current clinical practice for patients affected by chronic myeloid leukemia (CML) is based on the evaluation of second generation alternatives following therapeutic failure that leads to a lengthening of patients' management times and a consequent negative impact in terms of quality of life. Objective: To determine the economic absorption of resources associated to the management of patients with CML in a scenario in which an early recourse to ponatinib is considered as compared with a scenario based on the current Italian clinical practice characterized by a cyclical recourse to the available therapies. Methods: A Budget Impact model was developed to compare the resources absorbed in the scenarios under assessment considering a 3-year time horizon and the perspective of the Italian National Health Service. Results are expressed in terms of differential resources absorbed in the alternative scenarios. Results: The increase in the recourse to ponatinib allowed a saving of resources for the Italian NHS over the 3-year time horizon of -€ 1,979,322 (€ 825,104,350 vs € 823,125,028). The parameter affecting the most of the results achieved in the base-case is the monthly cost of bosutinib used as a third-line treatment. Conclusions: The increase in the recourse to ponatinib in patients affected by CML that failed to respond to a previous pharmacological therapy resulted to be associated to a lower level of resources' absorption in the Italian NHS allowing to re-allocate health founds to other fields of the care sector ensuring greater sustainability of the system. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Il burden economico dell'inappropriatezza prescrittiva nella gestione dell'osteoartrite in Italia.
- Author
-
Basile, Michele, Rumi, Filippo, Palmeri, Marco, Mattozzi, Ivano, Manzoli, Lamberto, Mammucari, Massimo, Gigliotti, Sergio, Bernabei, Roberto, and Cicchetti, Americo
- Abstract
Introduction: Osteoarthritis (OA) is a common chronic joint disease characterized by pain, deformity, instability, reduction of motion and function. It is one of the main causes of disability in older adults, affecting about 10% of men and 18% of women over the age of sixty. There are several Guidelines that support the general clinical decision-making process. However, it is necessary to define an integrated management model for patients with OA to ensure an appropriate and quality healthcare. Methods: The objective of the analysis is to determine the economic burden linked to the prevalence and incidence of OA in the acute and chronic phases from the perspective of the National Health Service (NHS) and the entire society. A comparison was made between the management according to the clinical practice and the appropriate management according to National and International Guidelines, determining for each scenario the level of resources absorbed. Results: Patients who started a nonsteroidal anti-inflammatory drug (NSAID)-based therapy in clinical practice resulted in a higher absorption of resources of €363.87 than the same patient managed by referring to National and International Guidelines. Conclusions: OA is associated with a high economic burden and it is a priority problem for public health internationally. The savings resulting from our research, if generalized to the entire Italian population, would lead to a signifi- cant reduction of OA economic burden, thus allowing a reallocation of the available resources to other NHS' sectors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. OP174 Health Technology Assessment And Economic Evaluations For A Genomic Strategy In Italy.
- Author
-
Di Brino, Eugenio, Antonini, Debora, Falasca, Giulia, Basile, Michele, Rumi, Filippo, and Cicchetti, Americo
- Abstract
Introduction: The challenge to health systems is sustainability, not only in the economic and financial sense of compatibility of spending with allocated resources, but also in terms of equity in access to services and care, quality, safety, innovation and research, that is, in terms of the effectiveness of the right to health. Some countries, such as Italy, do not have formal health technology assessment (HTA) or other similar processes that take into account views outside the decision maker. Methods: In the Italian national context, there is currently no single tariff for the reimbursability and pricing of genomic technologies. In fact, although genomic tests have been in clinical practice for many years now, to date they have not yet been included in the LEA (Minimum healthcare provision), especially in view of the fact that a defined and transparent process for updating the Essential Levels of Care has been operational since 2018. With the goal of structuring guidelines for the adaptability of economic evaluations to currently available and developing genomic technologies, a literature review was conducted. Results: The literature review showed that there are some methodological and practical issues that need to be carefully considered when designing and conducting economic evaluations of genomic tests. In more detail, five key concepts were identified in order to implement the most comprehensive economic evaluation of the technologies under study: the PICO model, the survey perspective, the costs included in the analysis, the effectiveness analysis, the time horizon, and the discount rate. Conclusions: Adequate definition of these concepts appears to be of paramount importance in view of the fact that genomic testing may have important consequences for future generations as well. For the purpose of sustainability of access of genomic technologies, the use of Budget Impact Analysis (BIA) is recommended in all analysis settings being essential for the regulator to tie access to its available budget capacity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. "Farmaci insostenibili" e giustizia intergenerazionale in Sanità.
- Author
-
REFOLO, PIETRO, SACCHINI, DARIO, RUMI, FILIPPO, CICCHETTI, AMERICO, and SPAGNOLO, ANTONIO G.
- Subjects
DISTRIBUTIVE justice ,DEBATE ,SUPPLY & demand ,HEPATITIS C ,ANTIVIRAL agents ,EQUALITY ,ENVIRONMENTAL justice ,INTERGENERATIONAL relations - Abstract
Copyright of Medicina e Morale is the property of PAGEPress and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
20. SIR-Spheres® Y-90 resin microspheres in chemotherapy refractory or intolerant patients with metastatic colorectal cancer.
- Author
-
Coretti, Silvia, Rumi, Filippo, Sacchini, Dario, and Cicchetti, Americo
- Subjects
COLON cancer treatment ,CANCER chemotherapy ,RADIOEMBOLIZATION ,EPIDERMAL growth factor receptors ,CANCER invasiveness - Published
- 2019
- Full Text
- View/download PDF
21. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.
- Author
-
Cicchetti, Americo, Coretti, Silvia, Sacco, Francesco, Rebulla, Paolo, Fiore, Alessandra, Rumi, Filippo, Di Bidino, Rossella, Urbina, Luz I., Refolo, Pietro, Sacchini, Dario, Spagnolo, Antonio G., Midolo, Emanuela, Marano, Giuseppe, Farina, Blandina, Pati, Ilaria, Veropalumbo, Eva, Pupella, Simonetta, and Liumbruno, Giancarlo M.
- Published
- 2018
- Full Text
- View/download PDF
22. PP13 Development Of Recommendations And Proposal For A Value-Based Managed Entry Agreement For Italian Setting.
- Author
-
Cicchetti, Americo, Xoxi, Entela, and Rumi, Filippo
- Abstract
Introduction: The continuous and pressing challenge that the drug regulatory authorities in Italy and in Europe are facing is that of guaranteeing patients' quick access to new drugs, ensuring the economic sustainability of the system at the same time. In recent years, flexible and diversified approaches have been developed known as Managed Entry Agreements (MEA). Methods: We performed an analysis of the Italian legislative and regulatory aspects in reference to a new Value-based Managed Entry Agreement (VBMEA) pathway. Thus, we tried to investigate the rationale for a new pathway analyzing three main dimensions related to the new medical product (MP): value; time to entry access; and, data quality and registry design. Moreover, we shared the discussion of the proposal with an international experts' panel. Results: The proposal for a new pathway of VBMEA from a procedural point of view shows the novelty related to the possibility to organize joint CTS (Technical Scientific Committee) and CPR (Price and Reimbursement Committee) assessment. A 24-month contract with an ex-factory price (PP) equal to X EUR per dose and a transfer price to the National Public Health System (NPHS), following application of a confidential discount for public structures (-X%), of X EUR per dose. After 24-months, an analysis of VBMEA is carried out. The price of the MP is therefore established based on AIFA registries and VBMEA results. The cost value incurred by the NPHS, intended as the difference between the price in market (entry) access phase and the price negotiated (PVB) in the light of the VBMEA results, shall be returned by the pharmaceutical company in the form of a payback. Conclusions: Currently, MEAs represent one of the main topics of discussion between the European National Payers Authorities. There is very little information on product performance that results from MEAs. This research project could provide advice to policy makers to decrease negotiation time by ensuring earlier access to innovation for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. The cost-effectiveness of an eradication programme in the end game: Evidence from guinea worm disease.
- Author
-
Fitzpatrick, Christopher, Sankara, Dieudonné P., Agua, Junerlyn Farah, Jonnalagedda, Lakshmi, Rumi, Filippo, Weiss, Adam, Braden, Matthew, Ruiz-Tiben, Ernesto, Kruse, Nicole, Braband, Kate, and Biswas, Gautam
- Subjects
TROPICAL medicine ,DRACUNCULIASIS ,MEDICAL care costs ,WORMS - Abstract
Background: Of the three diseases targeted for eradication by WHO, two are so-called Neglected Tropical Diseases (NTDs)–guinea worm disease (GWD) and yaws. The Guinea Worm Eradication Programme (GWEP) is in its final stages, with only 25 reported in 2016. However, global eradication still requires certification by WHO of the absence of transmission in all countries. We analyze the cost-effectiveness of the GWEP in the end game, when the number of cases is lower and the cost per case is higher than at any other time. Ours is the first economic evaluation of the GWEP since a World Bank study in 1997. Methods: Using data from the GWEP, we estimate the cost of the implementation, pre-certification and certification stages. We model cost-effectiveness in the period 1986–2030. We compare the GWEP to two alternative scenarios: doing nothing (no intervention since 1986) and control (only surveillance and outbreak response during 2016–2030). We report the cost per case averted, cost per disability adjusted life year (DALY) averted and cost per at-risk life year averted. We assess cost-effectiveness against a threshold of about one half GDP per capita (less than US$ 500 in low income countries). All costs are expressed in US$ of 2015. Results: The GWEP cost an estimated US$ 11 (95% uncertainty interval, 4.70–12.49) per case averted in the period 1986–2030. The pre-certification and certification phases can cost as much as US$ 0.0041 and US$ 0.0015 per capita per year. The cost per DALY averted by the GWEP relative to doing nothing is estimated at US$ 222 (118–372) in 1986–2030. The GWEP is probably more cost-effective than control by the year 2030. The GWEP is certainly more cost-effective than control if willingness to pay for one year of life lived without the risk of GWD exceeds US$ 0.10. Discussion: Even if economic costs are two times as high as the financial costs estimated for the period to 2020, the GWEP will still be cost-effective relative to doing nothing. Whether the GWEP turns out to be the most cost-effective alternative in the period beyond 2015 depends on the time horizon. When framed in terms of the number of years of life lived without the risk of GWD, a case can be made more easily for finishing the end game, including certification of the absence of transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
24. OP127 The Cost Effectiveness Of Anti-Vascular Endothelial Growth Factor Treatments For Age-Related Macular Degeneration In The Italian Healthcare Setting.
- Author
-
Basile, Michele, Di Brino, Eugenio, Rumi, Filippo, and Cicchetti, Americo
- Abstract
Introduction: Age-related macular degeneration (AMD) is a common condition that affects the middle part of a patient's vision. Typically, it first appears in people in their 50s and 60s. While it does not cause total blindness, it can make everyday activities, such as reading and recognizing faces, more difficult. This analysis aimed to define the resource absorption and cost-effectiveness profiles of the anti-vascular endothelial growth factor therapies currently available in the Italian healthcare context. Methods: A questionnaire was prepared to gather information on specific drivers involved in the provision pathway. The economic analysis was conducted according to activity-based costing methods. A cost-effectiveness analysis was carried out to provide information on the sustainability profile of the treatments available in the Italian setting. Results were reported in terms of the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were carried out to test the robustness of the results. Results: The average absorption of resources per patient along the whole clinical pathway for aflibercept, bevacizumab, ranibizumab, and brolucizumab was EUR6,858, EUR1,420, EUR7,930, and EUR5,667, respectively. Brolucizumab was characterized by an unacceptable cost-effectiveness profile (ICER EUR43,454) versus bevacizumab, considering a willingness-to-pay threshold of EUR40,000 per quality-adjusted life-year (QALY). Compared with ranibizumab, brolucizumab was associated with lower costs (EUR22,368 versus EUR29,333) and higher QALYs (12.8 versus 12.6). Brolucizumab had a higher level of QALYs (12.8 vs 12.7) and lower resources absorbed than aflibercept, with a saving of EUR4,222. Therefore, brolucizumab was a dominant alternative to ranibizumab and aflibercept. Conclusions: The analysis underlined how brolucizumab is a cost-saving strategy, compared with aflibercept and ranibizumab, and is likely to be cost-effective relative to bevacizumab in the Italian healthcare context. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. PP153 The Economic And Fiscal Impact Of Public Health Programs For Diabetic Patients In Italy.
- Author
-
Di Brino, Eugenio, Basile, Michele, Rumi, Filippo, Calabrò, Giovanna Elisa, and Cicchetti, Americo
- Abstract
Introduction: Technological innovations in the health sector have economic implications that go beyond their effects on health expenditure, expanding into other areas of the state budget (e.g., the social security system). Furthermore, innovation can affect the production of wealth by workers and companies, which in turn affects tax revenues. In addition, the presence of chronic diseases tends to reduce the propensity to consume and changes the allocation of consumption between the different sectors. Allocative decisions in the health system are rarely supported by an analysis that combines the health effects of innovations and their consequences in the economic system. Methods: The objective of this study was to estimate the value of management programs for patients suffering from type 2 diabetes mellitus that involved different levels of use of innovative technologies and drugs. A tax impact assessment methodology was adopted in the context of chronic conditions to analyze the effect of adopting alternative management models for patients with diabetes on the broader economic system. Results: Assuming a policy that reduces annual complications by 0.42 percent, there was an increase in tax revenue (cumulative value) of approximately EUR 28,175 and a reduction in productivity losses (cumulative value) of EUR 4,049,890. Projecting the impact on the age trend of the population up to 65 years of age with these estimates, it is possible to have an increase in tax revenue (cumulative value) equal to approximately EUR 7,050,598 and a reduction in productivity losses (cumulative value) equal to EUR 140,235,923. Conclusions: In light of this work, providing remote patient support (telemedicine) and expanding the provision of innovative oral antidiabetic drugs to family physicians could improve care for patients with type 2 diabetes mellitus. This study provides decision makers with an immediately usable model to broaden the information base for planning and regulatory choices. In addition, it supports the use of economic evaluations that calculate the entire value of a technological innovation or health program. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. PP108 Multidimensional Analysis Of Peristeen Plus Medical Device.
- Author
-
Cicchetti, Americo, Fiore, Alessandra, Rumi, Filippo, Di Paolo, Maria Giovanna, and Fortunato, Agostino
- Abstract
Introduction: Neurogenic bowel dysfunction occurs in people with central nervous system disease or injury and causes loss of bowel control and severe constipation. These problems involve a lot of anxiety and discomfort and can reduce the quality of life of those who suffer from them, therefore the management of symptoms is very important. Peristeen Plus is a transanal irrigation (TAI) system for bowel dysfunction management, used to empty the rectum and distal sigmoid colon, to prevent uncontrolled bowel movements or to relieve and prevent constipation. Methods: A literature review was conducted. A total of 14 records were included to evaluate the benefits in terms of efficacy and safety associated with the adoption of the medical device. To assess the economic impact, two different budget impact models have been implemented. The first aimed at evaluating an incremental diffusion in a short-term time horizon (3 years) of the home distribution of the device compared to the direct and indirect distribution methods in the Italian context. The second model aimed at assessing the impact of the diffusion of the device in the clinical practice. Results: Overall, most studies demonstrate improved endpoints related to the severity of fecal incontinence, constipation and intestinal disorders in patients using the device. The economic assessments conducted estimate that the increase in the Italian care setting is associated with a saving of resources in each year under analysis. The diffusion of home distribution of the device would potentially be able to offer a lower absorption of resources compared to other distribution methods. In addition to this, there is an incremental saving correlated to the degree of diffusion of Peristeen Plus. Conclusions: TAI is considered a safe and more effective method than conventional treatments for reducing fecal incontinence, constipation and improving quality of life. The results of our study confirm the benefits of TAI as a second-line treatment in case of failure of conventional medical therapy in the management of the neurogenic gut. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. PP85 The Cost-Effectiveness Of The Anti-COVID Vaccination Campaign In The Italian Healthcare Setting.
- Author
-
Basile, Michele, Di Brino, Eugenio, Rumi, Filippo, and Cicchetti, Americo
- Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms of COVID-19 are variable, but often include fever, cough, headache, fatigue, breathing difficulties, and loss of smell and taste. Symptoms may begin one to fourteen days after exposure to the virus. COVID-19 transmits when people breathe in air contaminated by droplets and small airborne particles containing the virus. The present analysis aims to define the cost-effectiveness profile of the anti-COVID vaccination campaign in the Italian healthcare setting. Methods: The analysis was based on the collection and analysis of data regarding the number of hospitalizations (ordinary regime and intensive care) and infections recorded by the Italian Ministry of Health in vaccinated and unvaccinated patient cohorts. The acquisition costs of the available vaccine alternatives were considered as well as the cost of the personnel involved in the vaccination campaign. The reduction in hospitalizations was considered as a measure of effectiveness. We have compared the current scenario of campaign vaccination versus a scenario in which the total of the eligible population would be vaccinated. Results are reported in terms of Incremental Cost Effectiveness Ratio (ICER). Deterministic and probabilistic sensitivity analyses were carried out in order to test the robustness of the results. Results: The vaccination campaign allowed for savings amounting to EUR 9,398,012.10 (EUR 60,499,053.25 vs EUR 69,897,065.35) and 6,647 hospitalizations avoided (715 and 5,932 in the intensive care and ordinary regimen, respectively), thus resulting a dominant strategy as compared with the alternative (no vaccination). As the cost-effectiveness profile of the campaign improves, we should consider the period (May-July 2021), during which the daily threshold of 500,000 doses administered on a national basis was consistently exceeded. Conclusions: The analysis underlined how the vaccination campaign represents a cost-saving alternative in the Italian healthcare setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. PP83 Economic Impact Of Missed Vaccinations On The Italian National Health System.
- Author
-
Di Brino, Eugenio, Basile, Michele, Rumi, Filippo, and Cicchetti, Americo
- Abstract
Introduction: To provide a complete picture of the economic impact of the coronavirus disease 2019 (COVID-19) emergency for the Italian National Health System (NHS), an estimate was made of the costs to the NHS of vaccination hesitation. The concept of economic impact was investigated with reference to the volume of hospitalizations and days of intensive care required for patients with COVID-19 related to missed vaccinations, considering a vaccine efficacy of less than 100 percent. Methods: Data from the Istituto Superiore di Sanità were analyzed with respect to the number of people vaccinated in the general population, and the number of people with severe acute respiratory syndrome coronavirus 2 infection who were hospitalized or died in a one-month period stratified by vaccination status. The costs for unvaccinated patients admitted to a general hospital ward (Medical Area) or the intensive care unit were calculated. Results: Based on the number of preventable hospitalizations among unvaccinated people, the economic impact of missed vaccinations on the NHS in the 30-day period from 13 August 2021 to 12 September 2021 was estimated. Among the unvaccinated hospitalized patients, 5,932 would have avoided hospitalization in the Medical Area and 715 would have avoided admission to the intensive care unit. Thus, each unvaccinated hospitalized patient had an average per capita cost of EUR 17,408. The total costs amounted to EUR 69,894,715, comprising EUR 51,166,079 for hospitalizations in the Medical Area and EUR 18,728,636 for hospitalizations in intensive care. Conclusions: By evaluating the weekly incidence of hospitalizations per 100,000 people stratified by vaccination status (unvaccinated, partially vaccinated, and fully vaccinated), it is possible to see that we are facing two distinct pandemics running together. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. PP59 Multidimensional Evaluation Of The Reducer Device In Patients With Refractory Angina.
- Author
-
Cicchetti, Americo, Rumi, Filippo, Siviero, Ludovica, and Fortunato, Agostino
- Abstract
Introduction: Treatments for coronary heart disease patients have had major developments in recent decades, both in the pharmacological and interventional fields, and this has helped to prolong the survival of these patients. However, the growing number of patients who show persistent and disabling symptoms of angina proves that at the same time their quality of life has not been equally improved. Methods: We conducted a multidimensional assessment coherent with health technology assessment methodology on the Coronary Sinus Reducer System (CSRS). CSRS is the latest line of therapy for patients with coronary artery disease who are ineligible for revascularization, demonstrate reversible ischemia, and have refractory angina pectoris (AP) despite optimal standard medical therapy. We performed a literature review in order to gather evidence on efficacy and safety of the device and on the economic and organizational impact of the procedure. In the economic domain we developed a cost-utility model based on a decision tree and a five-year time horizon budget impact model. Results: Several studies in the literature have shown that this therapy is related to an increase in quality of life and an improvement in symptoms of refractory angina. The economic evaluations conducted show how the therapy, despite an increase in the resources absorbed in the first years of implementation, reaches a cost saving profile in the medium term due to positive outcomes, while leading to an increase in the quality of life in patients suffering from refractory angina. Conclusions: The treatment of refractory angina remains a challenge for today's medicine. Patients suffering from this condition are often described as "no option" patients. Thus, despite there is a need of further evidence to establish even more robustly the economic sustainability of the device, especially on its effectiveness in the medium-long term, the device should be taking into account in those patients who could benefit from it in terms of relieving the symptoms of angina and improving their quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. PP32 Assessment Of Preferences For Treatment: A Discrete Choice Experiment Among Italian Patients With Prostate Cancer.
- Author
-
Di Brino, Eugenio, Di Bidino, Rossella, Basile, Michele, Rumi, Filippo, Beccaglia, Patrizia, Vetrini, Damir, and Cicchetti, Americo
- Abstract
Introduction: The integrated patient-centered, evidence-based approach to care recognizes the role of patient preferences. A discrete choice experiment (DCE) was developed with the aim of identifying the preferences of men with prostate cancer in Italy regarding the different risk-benefit factors of various treatment options. Methods: The DCE was developed with the support of prostate cancer patients and oncologists and was based on a targeted scoping review. The final DCE included 26 choice sets divided into two blocks. The first block focused on all prostate cancer patients (both metastatic and non-metastatic), while the second block aimed to assess preferences for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Patients were asked to choose from ten attributes in the first block and six in the second block. The aim was to identify attributes and levels with a statistically significant impact on patient preferences. Preference estimates were calculated using a conditional logit regression model and the results were stratified by cancer stage (metastatic or non-metastatic) in the first block. Results: A total of 202 patients (mean age 72 years) completed the DCE. In the first block, the most important attribute was quality of life (QoL), particularly for patients with metastatic cancer. The other three attributes found to be significant, in order of relevance to patients, were the risks of experiencing cognitive impairment, hematologic complications, and fatigue. For patients with mHSPC, QoL was the strongest determinant of preference. The risk of experiencing fatigue was also a relevant attribute, followed by skin irritation. Conclusions: This study shows that the effect of treatment on QoL was the most important attribute for patients diagnosed with prostate cancer. Specific risk factors play a different role in the choice of treatment depending on cancer type, with the risk of experiencing fatigue being valued by all groups. Identifying and understanding patients' preferences related to treatments for prostate cancer will help physicians identify the best treatment strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Evaluation of the economic impact of the robotic approach in major and postero-superior segment liver resections: a multicenter retrospective analysis.
- Author
-
Ingallinella S, Ardito F, Ratti F, Marino R, Catena M, De Rose AM, Razionale F, Rumi F, Cicchetti A, Giuliante F, and Aldrighetti L
- Abstract
Background: Economic impact of robotic liver surgery (RLS) is still a debated issue due to the heterogeneity of liver resections considered and the lack of a rigorous methodology. Therefore, the aim of this study is to perform a time-driven activity-based costing (TD-ABC) comparing the costs of RLS, laparoscopic liver surgery (LLS) and open liver surgery (OLS) in the context of complex liver resections and to compare short term perioperative outcomes., Methods: The institutional databases of two Italian high volume hepatobiliary centres were retrospectively reviewed from February 2021 to April 2022. Patients submitted to major hepatectomies or postero-superior liver resections were selected and divided into three groups according to the approach scheduled (RLS, LLS and OLS) and compared. Major contributors of perioperative expenses were calculated using the TD-ABC model and accurately quantifying each unit resource consumed per patient and the time spent performing each activity. A primary intention-to-treat analysis (ITT-A) including conversions in the RLS and LLS groups was performed., Results: Forty-seven RLS, 101 LLS and 124 OLS were collected. LLS and RLS showed reduced blood loss, morbidity, mortality and hospital stay compared with open. A trend towards reduced conversion rate in RLS compared to LLS was registered. Total costs associated with RLS were estimated at €10,637 vs. €9,543 for LLS and vs. €13,960 for OLS. The higher intraoperative costs associated with RLS (+153.3% vs. OLS and +148.2% vs. LLS, P<0.001), primarily related to surgical equipment expenses, were slightly offset by the postoperative savings (-56.0% vs. OLS and -29.4% vs. LLS, P<0.001) resulting from significantly reduced hospital stays., Conclusions: RLS offers economic advantages over OLS, as initial higher costs are offset by better perioperative outcomes. The evolving robotic marketplace is expected to drive down RLS costs, promoting widespread adoption in minimally invasive procedures. Despite its higher costs than LLS, RLS's ability to enhance minimally invasive feasibility makes it a preferred choice for complex cases, reducing the need for conversions., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-407/coif). L.A. serves as an unpaid editorial board member of Hepatobiliary Surgery and Nutrition. The other authors have no conflicts of interest to declare., (2024 Hepatobiliary Surgery and Nutrition. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Il burden clinico ed economico delle complicanze della cute peristomale: un’analisi di Activity Based Costing.
- Author
-
Fortunato A, Rumi F, Zazzetta M, Valle MD, Pedace V, and Cicchetti A
- Published
- 2024
- Full Text
- View/download PDF
33. Feasibility study on a new enhanced device for patients with intermittent catheterization (LUJA).
- Author
-
Calabrò GE, D'Ambrosio F, Orsini F, Pappalardo C, Scardigno A, Rumi F, Fiore A, Ricciardi R, and Cicchetti A
- Subjects
- Humans, Feasibility Studies, Urinary Catheterization, Self Care
- Published
- 2023
- Full Text
- View/download PDF
34. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population.
- Author
-
Rumi F, Basile M, Cicchetti A, Alvarez FP, Azzi MV, and Muzii B
- Subjects
- Humans, Aged, Cost-Benefit Analysis, State Medicine, Italy, Vaccines, Combined, Influenza Vaccines, Influenza, Human prevention & control, Influenza, Human epidemiology
- Abstract
Objectives: To assess the cost-effectiveness of switching from adjuvanted quadrivalent vaccine (aQIV) to high-dose quadrivalent influenza vaccine (HD-QIV) in those aged ≥65 years from the Italian National Health Service perspective., Methods: We developed a decision tree model over a 1-year time-horizon to assess influenza-related costs and health outcomes. Two hospitalization approaches were considered: "hospitalization conditional on developing influenza" and "hospitalization possibly related to Influenza." The first approach considered only hospitalizations with influenza ICD-9-CM diagnosis codes. The second included hospitalizations for cardiorespiratory events possibly related to influenza to better capture the "hidden burden". Since comparative efficacy of high-dose quadrivalent influenza vaccine versus adjuvanted quadrivalent vaccine was lacking, we assumed relative efficacy versus a common comparator, standard-dose influenza quadrivalent vaccines (SD-QIV). We assumed the relative efficacy of HD-QIV vs. SD-QIV was 24.2 and 18.2% for the first and second hospitalization approaches, respectively, based on published information. Due to lack of comparative efficacy data for aQIV vs. SD-QIV, we assumed three different scenarios: 0, 6, and 12% relative efficacy in scenarios 1, 2, and 3, respectively., Results: For the first hospitalization approach, HD-QIV was a cost-effective alternative to aQIV in all scenarios at a willingness-to-pay threshold of €30,000 per Quality Adjusted Life Years. The incremental cost-effectiveness ratios across the scenarios were €7,301, €9,805, and €14,733, respectively, much lower than the willingness-to-pay per Quality Adjusted Life Years threshold. For the second hospitalization approach, HD-QIV was a dominant alternative to aQIV across all scenarios. The robustness of the results was confirmed in one-way and probabilistic sensitivity analyses., Conclusion: Switching to HD-QIV from aQIV for the older adult in Italy would improve health-related outcomes, and would be cost-effective or cost saving., Competing Interests: FA, MA, and BM are employees of Sanofi and may hold shares and/or stock options in the company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Rumi, Basile, Cicchetti, Alvarez, Azzi and Muzii.)
- Published
- 2023
- Full Text
- View/download PDF
35. Analysis of heterogeneity of the different health technology assessment reports produced on the transcatheter aortic valve implantation in patients with severe aortic valve stenosis at low surgical risk.
- Author
-
Rumi F, Fortunato A, Antonini D, Siviero L, and Cicchetti A
- Abstract
Background: Symptomatic severe aortic stenosis is a congenital or acquired aortic valve disease that occurs when the aortic valve of the heart narrows. It represents the most common valvular disease in adults and generally has a degenerative nature. Transcatheter aortic valve implantation (TAVI), due to its non-invasive approach, has become the standard treatment in patients who are ineligible to surgery or at high surgical risk, and it is also increasingly being performed in patients at intermediate to low surgical risk. The aim is to analyze the heterogeneity and explore the limitations of current health technology assessments (HTAs) on TAVI., Methods: For the purpose of this analysis, a review of the literature based on manual research was performed. A population, intervention, comparators, and outcome (PICO) model was used to gather the HTA reports assessing TAVI in the treatment of patients affected by symptomatic severe aortic valve stenosis at low surgical risk. Furthermore, a manual search has been developed to also include assessments from the Haute Autorité de Santé., Results: At the end of the investigation, a certain degree of heterogeneity in the evidence factored and in the recommendations on the technology has emerged. Relative to the clinical domains, the main drivers for the disparity are found in the type of evidence considered and in the use or not of the grading of recommendations, assessment, development, and evaluation (GRADE) methodology to evaluate the quality of the clinical evidence included. Another element concerns the chosen device generation assessed within the evaluation. In order to perform the economic evaluation, a cost-utility analysis and a budget impact model were developed. Despite some elements of heterogeneity, the economic assessments demonstrate a favorable or dominant cost-effectiveness profile for TAVI compared with surgical aortic valve replacement (SAVR)., Conclusion: Despite the presence of heterogeneity elements both in clinical and economic domains, HTA agencies reached the same recommendations on the use of TAVI. It emerged the need for a centralized vision on the "strong" domains, which means giving up freedom to local bodies to adapt to their context on the "soft" ones. This approach could have the potential to strengthen the role of HTA in Europe by ensuring faster decision-making and equity of access to health innovations and reduce the heterogeneity in the assessment methods., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Edwards Lifesciences. The funder had the following involvement in the study: revision of the final version of the manuscript., (© 2023 Rumi, Fortunato, Antonini, Siviero and Cicchetti.)
- Published
- 2023
- Full Text
- View/download PDF
36. Analysis of the multidisciplinary approach for the management of patients affected by chronic myeloid leukaemia.
- Author
-
Basile M, Di Brino E, Rumi F, Palmeri M, and Cicchetti A
- Abstract
Background: Chronic myelogenous leukaemia (CML) is a pathological clinical condition with a yearly incidence between 10 and 15 cases per million people, 14 in Italy. Its incidence increases with age, reaching 20-25 yearly cases per million individuals in people over 70 years. A growing importance has been given to the need of a multidisciplinary approach (MDA) for the management of patients with CML., Objective: To analyse the importance of MDA as compared with the current Italian standard of care for the management of CML patients based on the involvement of several health professional figures., Methods: A group of healthcare professionals from several healthcare structures were gathered in a first Advisory Board (AB) and divided into as many groups as the number of belonging health structures representative of the Italian provision of therapeutic approaches for CML. In a second AB, the results were validated by the same panel of experts., Results: The number of dedicated health professionals within the dedicated ward ranged from 1 to 13. Most structures rely on several professionals intervening only in case of necessity. Only one centre provides a booking service based on clinical needs to avoid waiting times. Most centres report there is basically no disagreement in the definition of the clinical pathway and there is a high adherence to national and international CML guidelines., Conclusions: The development of forms of interorganisational and interprofessional coordination to improve the diagnosis and the treatment of CML patients have been for long on the agenda of policy makers, managers and professionals for more than 20 years. This analysis represents a starting reference to consider for the evaluation of an MDA in the Italian context., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
37. [Flu vaccination and value-based health care: operational solutions to safeguard public health].
- Author
-
Calabrò GE, Icardi G, Bonanni P, Gabutti G, Vitale F, Rizzo C, Cicchetti A, Staiano A, Ansaldi F, Orsi A, DE Waure C, Panatto D, Amicizia D, Bert F, Villani A, Ieraci R, Conversano M, Russo C, Rumi F, Scotti S, Maio T, Russo R, Vaccaro CM, Siliquini R, and Ricciardi W
- Subjects
- Humans, Public Health, Vaccination, Health Facilities, Delivery of Health Care, Influenza, Human, Influenza Vaccines
- Published
- 2022
- Full Text
- View/download PDF
38. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
- Author
-
Xoxi E, Rumi F, Kanavos P, Dauben HP, Gutierrez-Ibarluzea I, Wong O, Rasi G, and Cicchetti A
- Abstract
Managed entry agreements (MEA) represent one of the main topics of discussion between the European National Payers Authorities. Several initiatives on the subject have been organized over the past few years and the scientific literature is full of publications on the subject. There is currently little international sharing of information between payers, mainly as a result of the confidentiality issues. There are potential benefits from the mutual sharing of information, both about the existence of MEAs and on the outcomes and results. The importance of involving all the players in the decision-making process on market access for a medicinal product (MP) is that it may help to make new therapies available to patients in a shorter time. The aim of this project is to propose a new pathway of value-based MEA (VBMEA), based on the analysis of the current Italian pricing and reimbursement framework. This requires elaboration of a transparent appraisal and MEA details with at least a 24-month contract. The price of the MP is therefore valued based on the analysis of the VBMEA registries of the Italian Medicines Agency. Although the proposal focuses on the Italian context, a similar approach could also be adapted in other nations, considering the particularities of the single health technology assessment (HTA)/payer system., Competing Interests: OW was employed by Medi-Qualité Omega. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Xoxi, Rumi, Kanavos, Dauben, Gutierrez-Ibarluzea, Wong, Rasi and Cicchetti.)
- Published
- 2022
- Full Text
- View/download PDF
39. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.
- Author
-
Cicchetti A, Coretti S, Sacco F, Rebulla P, Fiore A, Rumi F, Di Bidino R, Urbina LI, Refolo P, Sacchini D, Spagnolo AG, Midolo E, Marano G, Farina B, Pati I, Veropalumbo E, Pupella S, and Liumbruno GM
- Subjects
- Adult, Costs and Cost Analysis, Disinfection methods, Female, Humans, Italy, Male, Blood Platelets, Disinfection economics, Platelet Transfusion economics
- Abstract
Background: Despite improvements in blood donor selection and screening procedures, transfusion recipients can still develop complications related to infections by known and emerging pathogens. Pathogen reduction technologies (PRT) have been developed to reduce such risks. The present study, developed whithin a wider health technology assessment (HTA) process, was undertaken to estimate the costs of the continuing increase in the use of platelet PRT in Italy., Materials and Methods: A multidisciplinary team was established to perform the HTA and conduct a budget impact analysis. Quantitative data on platelet use were derived from the 2015 national blood transfusion report and from the Italian Platelets Transfusion Assessment Study (IPTAS). The current national fee of 60 Euro per platelet PRT procedure was used to quantify the costs to the Italian National Health Service (INHS). The analysis adopts a 3-year time-frame. In order to identify the impact on budget we compared a scenario representing an increased use of PRT platelets over time with a control scenario in which standard platelets are used., Results: Progressive implementation of PRT for 20%, 40% and 66% of annual adult platelet doses could generate an increase in annual costs for the INHS amounting to approximately 7, 14 and 23 million Euros, respectively. Use of kits and devices suitable for the treatment of multiple adult platelet doses in one PRT procedure could lower costs., Discussion: In order to fully evaluate the societal perspective of implementing platelet PRT, the increase in costs must be balanced against the expected benefits (prevention of transfusion-transmissible infections, white cell inactivation, extension of platelet storage, discontinuation of pathogen detection testing). Further studies based on actual numbers of platelet transfusion complications and their societal cost at a local level are needed to see the full cost to benefit ratio of platelet PRT implementation in Italy, and to promote equal treatment for all citizens.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.